Background: Tofacitinib is an oral, small molecule Janus kinase inhibitor that is being investigated for inflammatory bowel disease. Aims: This 48-week open-label extension study primarily investigated long-term safety of tofacitinib 5 and 10 mg b.d. and secondarily investigated efficacy as maintenance therapy in patients with Crohn's disease. Methods: Patients who had completed the phase 2b maintenance study, or withdrawn due to treatment failure, were enrolled. Patients in remission (Crohn's disease activity index <150) at baseline received tofacitinib 5 mg b.d.; all others received 10 mg b.d. A single dose adjustment was allowed after 8 weeks' fixed, open-label treatment. Results: Sixty-two patients received tofacitinib 5 mg b.d.; 88 received 10 mg b.d.
| INTRODUCTION
Crohn's disease is a chronic, progressive inflammatory disease of the gastrointestinal tract 1 that has a significant impact on patients' quality of life. 2 Current therapies for Crohn's disease include corticosteroids, thiopurines, methotrexate, anti-tumour necrosis factor α antibodies, anti-integrin antibodies and anti-p40 antibodies. 3 However, not all patients respond to these medications, leaving an unmet need for novel therapies. 4 Tofacitinib is an oral, small molecule Janus kinase inhibitor approved in several countries for the treatment of ulcerative colitis.
It has also been investigated for Crohn's disease. The efficacy and safety of tofacitinib for inducing and maintaining clinical remission (defined as Crohn's disease activity index [CDAI] score <150) in patients with moderate-to-severe Crohn's disease have previously been investigated in two phase 2b studies. 5 These induction and maintenance studies showed a modest treatment effect of tofacitinib compared with placebo, although the primary induction efficacy endpoint of clinical remission at week 8 was not significantly different from placebo. After 26 weeks of maintenance therapy, a higher proportion of patients receiving tofacitinib 10 mg twice daily (b.d.)
showed clinical response-100 (defined as a CDAI score reduction of at least 100 points from baseline) or remission vs placebo, although these differences were also not statistically significant. 5 Here, we present results of a phase 2b open-label extension study that evaluated the safety and tolerability of tofacitinib, and exploratory efficacy over 48 weeks of treatment and 4 weeks of follow-up. Guidelines. All patients provided written informed consent.
| MATERIALS AND METHODS

| Study design
| Study patients
To be eligible for this study, patients with Crohn's disease had either completed the 26-week, double-blind, maintenance study or had withdrawn from the maintenance study after meeting pre-specified treatment failure criteria. Maintenance study treatment failure was defined as meeting both of the following criteria on two consecutive visits, at least 2 weeks apart, in patients who had completed 
| Primary objective: safety outcomes
The primary objective was to investigate the long-term safety and 
| Secondary objective and secondary efficacy outcomes
The secondary objective was to investigate the effects of tofacitinib maintenance therapy on clinical remission, patient quality of life, and biomarkers measured by C-reactive protein and faecal calprotectin, through 48 weeks.
Secondary binary efficacy outcomes included clinical remission,
sustained clinical remission (achieved clinical remission at both weeks 24 and 48) and steroid-free clinical remission at week 48 among patients receiving steroids at baseline. Other endpoints included CDAI scores over time, time to relapse, serum high-sensitivity C-reactive protein and faecal calprotectin over time, changes from baseline, and corticosteroid use. Relapse was defined as an increase in CDAI of >100 points from baseline, and an absolute CDAI score of >220 points. The proportion of patients who relapsed, and the time to relapse, was analysed for patients in clinical remission at baseline who initially received tofacitinib 5 mg b.d. Also evaluated was the proportion of patients switching (at the investigator's discretion) from tofacitinib 5 to 10 mg b.d., or vice versa. Efficacy outcomes were monitored through 48 weeks, to end of treatment, or to early termination for those who discontinued the study.
| Patient-reported outcomes
The following patient-reported outcomes were collected during this open-label extension study: the Inflammatory Bowel Disease Questionnaire (IBDQ), 6 the Short Form-36 v2 (SF-36v2; physical and mental component summary scores [PCS/MCS] and eight domain scores, with a 1-week recall) 7 
and the European Quality of Life
Five Dimensions Questionnaire (EQ-5D) and Visual Analogue Scale (VAS) EQ-5D/VAS. 8 The inflammatory bowel disease Patient-Reported Treatment Impact (PRTI; v2) comprised three endpoints (patient satisfaction, preference for the study medication over their previous treatment, and willingness to use the study treatment again). 9, 10 Endpoints for IBDQ included: absolute scores and change from baseline in IBDQ total score and domain scores (ie, bowel symptoms, systemic symptoms, emotional function and social function) over time, IBDQ clinical remission (total score ≥170) at week 48, absolute scores and change from baseline in SF-36v2, EQ-5D/VAS over time, and absolute scores for PRTI at week 48. IBDQ scores were recorded at baseline, weeks 8, 24 and 48. SF-36v2 and EQ-5D/VAS scores were recorded at baseline, weeks 24 and 48, and PRTI was recorded at week 48. The number of patients hospitalised, and the length of hospitalisations related to Crohn's disease, was collected at every study visit. 
| Statistical analyses
| RESULTS
| Patients
A total of 150 patients were enrolled in this study. Of these, 62 patients in remission at entry were assigned tofacitinib 5 mg b.d., and 88 patients with active disease were assigned 10 mg b.d. Of Table S1 ). A greater proportion of patients assigned 10 mg b.d. were taking corticosteroids and had higher mean CDAI scores and higher median C-reactive protein and faecal calprotectin concentrations, compared with those receiving 5 mg b.d. (Table 1 ). Ileocolonic disease location was recorded in a numerically higher proportion of patients receiving tofacitinib 10 mg b.d. than 5 mg b.d.
| Safety outcomes
The proportion of patients with adverse events was 79.0% and 76.1% for tofacitinib 5 and 10 mg b.d., respectively ( Discontinuation due to insufficient clinical response was more frequent for patients who entered the study not in remission, receiving 10 mg b.d. (30.7%), compared with 5 mg b.d. (9.7%). By investigator decision, some cases of discontinuation due to insufficient clinical response did not have an associated adverse event of worsening Crohn's disease recorded, and one patient discontinued due to an adverse event of worsening Crohn's disease but did not have this specified as a reason for insufficient clinical response. Laboratory values meeting predetermined laboratory criteria for re-test or discontinuation were similarly low for both tofacitinib groups.
During this study, there were no deaths, adjudicated cases of cardiovascular events, interstitial lung disease or hepatic injury, or malignancy (excluding non-melanoma skin cancer [NMSC]) ( Table 2 ).
One case of basal cell carcinoma of the skin was reported in the Includes enrolled patients who received ≥1 dose of study medication. N represents the total number of patients in each group; n represents the number of patients with events. † Dose assignment was determined based on last available haematocrit result prior to open-label extension study entry. Baseline CDAI scores were recalculated using baseline haematocrit results received after treatment assignment was determined. Therefore, one patient in the tofacitinib 5 mg b.d. group and four patients in the 10 mg b.d. group had remission status that did not correspond to their initial dose assignment. b.d., twice daily; CDAI, Crohn's disease activity index
| Exploratory efficacy outcomes
This study had no primary efficacy endpoints; all efficacy endpoints, week 48 are shown in Table S2 ). For patients initially assigned 
| Patient-reported outcomes
For patients who entered the study in remission receiving tofacitinib 5 mg b.d., the majority (range: 69.5%-81.0%) showed high (≥170) IBDQ total scores at baseline, weeks 8, 24 and 48 (Figure 7) . At week 48, mean change from baseline IBDQ total score (−2.8) and
individual IBDQ domains showed a general maintenance of values over time, with change from baseline range −3.1-0.1 (see Table S3 ).
At week 48, small mean changes from baseline were observed for SF-36v2 domains (−0.2 and −1.2 for PCS and MCS, respectively), and for EQ-5D/VAS score (1.2). For PRTI assessment, 66.7% and 33.3% of patients reported being "extremely satisfied" or "satisfied," respectively, with their study drug, 88.1% of patients reported they preferred their study drug, and 83.3% reported they would use the same drug again.
In the tofacitinib 10 increasing proportion of patients with high (≥170) total IBDQ score through week 48, among those who remained in the study (see Table S3 ). Substantial improvements (37.2) in mean change from baseline for IBDQ total score were observed at week 48. Each individual IBDQ domain showed increases in values (range: 6.6-12.6) at
week 48.
At week 48 with tofacitinib 10 mg b.d., there were clinically relevant improvements in PCS and MCS of 8.4 and 7.6, respectively, greater than the previously published minimal clinically important differences of 1.6-4.0 and 2.3-5.7, respectively, using either a distribution-or effect size anchor-based approach. 11 At week 48, there were clinically relevant increments from baseline for the EQ-5D/VAS score of 21.2, greater than the minimal clinically important differences of 4.2-14.8. 11 For the PRTI assessment, 32.6% and 41.3% of patients reported being "extremely satisfied" or "satisfied" with their study drug, respectively. 56.5% of patients reported they preferred their study drug, and 60.9% reported they would use the same drug again.
| DISCUSSION
No new or unexpected safety signals were observed during this study. Rates of adverse events were generally similar for patients receiving tofacitinib 5 and 10 mg b.d. and were consistent with the previous 26-week maintenance study. 5 In the maintenance study, Crohn's disease worsening was also the most frequently occurring adverse event, 5 although rates were lower than those reported here. with up to 114 months' observation. 13 No new safety signals emerged and, as in the rheumatoid arthritis programme, the most frequently occurring adverse events were infections, including nasopharyngitis. 13 Rates of discontinuation due to adverse events and insufficient clinical response were higher for tofacitinib 10 mg b.d. than 5 mg b.d.,
Patient
indicating that patients who entered the open-label extension study in remission had a lower probability of experiencing insufficient clinical response resulting in discontinuation. Compared with the maintenance study, rates of discontinuation due to adverse events and discontinuation due to insufficient clinical response reported here were generally similar for tofacitinib 10 mg b.d. and lower for 5 mg b.d. 5 In this open-label extension study, rates of serious adverse events were higher with tofacitinib 10 mg b.d. than 5 mg b.d., and compared with rates observed in the maintenance study. 5 However, it is important to note that patients assigned 10 mg b.d. were not in remission at baseline, and were therefore likely to have more severe 9, 10 The majority of patients receiving tofacitinib reported positive outcomes of "extremely satisfied" and "satisfied" for the PRTI assessments of patient satisfaction.
Proportions of patients responding positively were slightly higher for 5 mg b.d. than 10 mg b.d.
This study had several limitations. Only patients not in remission were assigned tofacitinib 10 mg b.d.; therefore, as the two patient populations had different disease activity at the outset, this precluded definitive comparison of efficacy outcomes between doses.
Patients were permitted to switch doses after 8 weeks of receiving their initially assigned study dose and, as such, efficacy and safety outcomes were analysed by initial dose assignment, not taking dose changes into account. Additionally, this was an open-label study, without a control group.
In summary, no new safety signals were observed through week 52 of this open-label extension study of tofacitinib in patients with Crohn's disease. Rates of adverse events were generally similar among both groups, and were consistent with rates observed in the previous tofacitinib Crohn's disease maintenance study. There were higher rates of serious adverse events and discontinuation due to adverse events in the tofacitinib 10 mg b.d. group. However, as patients were only assigned tofacitinib 10 mg b.d. if they were not in remission at baseline and therefore had more active disease than those receiving 5 mg b.d., and because dose switching was permitted, direct comparisons between dose groups were not conducted.
Patients in remission at open-label extension study entry had a lower rate of discontinuation due to insufficient clinical response than those not in remission at study entry. Exploratory efficacy analyses at week 48 appeared to show that many patients receiving tofaci- 
| DATA SHARING STATEMENT
Upon request, and subject to certain criteria, conditions and exceptions (see https://www.pfizer.com/science/clinical-trials/trial-dataand-results for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines and medical devices (a) for indications that have been approved in the US and/or EU or (b) in programmes that have been terminated (ie, development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.
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